Results 181 to 190 of about 22,348 (214)
Some of the next articles are maybe not open access.
Mimics of axial spondyloarthritis
Current Opinion in Rheumatology, 2019Purpose of reviewAxial spondyloarthritis (AxSpA) is a distinct clinical entity with characteristic clinical and radiographic features; however, a multitude of other metabolic, infectious and inflammatory disorders mimic it both clinically and radiographically.Recent findingsWe present in this review article recent updates about the various disease ...
Sali, Merjanah +2 more
openaire +2 more sources
Axiale Spondyloarthritis erkennen
MSK – Muskuloskelettale Physiotherapie, 2021Magrey MN, Danve AS, Ermann J et al. Recognizing Axial Spondyloarthritis: A Guide for Primary Care. Mayo Clin Proc 2020; 95: 2499–2508.
openaire +1 more source
Axial Imaging in Spondyloarthritis
Rheumatic Disease Clinics of North AmericaImaging plays a crucial role in diagnosing and forecasting treatment outcomes in axial spondyloarthritis. Conventional radiography may overlook patients in the initial stages of the disease, while MRI is sensitive in identifying inflammation early on. Computed tomography reliably detects structural abnormalities. Practicing rheumatologists must possess
Vishnu, Mohan, Mark C, Hwang
openaire +2 more sources
Certolizumab pegol in axial spondyloarthritis
Expert Review of Clinical Immunology, 2013The axial spondyloarthritis (SpA) classification criteria cover both patients with ankylosing spondylitis and non-radiographic axial SpA. After failure of NSAIDs TNF-α-inhibitors (TNF-blockers) can be given to patients with active axial SpA. Until recently, the TNF-blockers infliximab, adalimumab, etanercept and golimumab are labeled for the treatment ...
In-Ho, Song, Martin, Rudwaleit
openaire +2 more sources
Biomarkers in axial spondyloarthritis
Current Opinion in Rheumatology, 2015To assess the literature for biomarker validation studies that address key unmet needs related to the evaluation and management of patients with axial spondyloarthritis (SpA). This review focused on biomarkers facilitating early diagnosis and reflecting disease activity, structural damage on radiography, and clinical response to major therapies.Early ...
openaire +2 more sources
Anti-TNFs in axial spondyloarthritis
Wiener Medizinische Wochenschrift, 2015Since there is no evidence regarding the efficacy of conventional synthetic disease modifying anti-rheumatic drugs in the improvement of axial spondyloarthritis (SpA), anti-tumor necrosis factors (anti-TNFs) are recommended if nonsteroidal anti-inflammatory drugs fail, or in case of high disease activity.
Roland, Kocijan +2 more
openaire +2 more sources
2016
Ankylosing spondylitis (AS) is a chronic inflammatory arthritis affecting mainly the sacroiliac joints and spine, resulting in pain, stiffness, and reduced movement. Over the past decade there have been major advances in many aspects of the disease, including a broadening of the disease description to axial spondyloarthritis (axSpA).
openaire +1 more source
Ankylosing spondylitis (AS) is a chronic inflammatory arthritis affecting mainly the sacroiliac joints and spine, resulting in pain, stiffness, and reduced movement. Over the past decade there have been major advances in many aspects of the disease, including a broadening of the disease description to axial spondyloarthritis (axSpA).
openaire +1 more source
Pembrolizumab-Induced Axial Spondyloarthritis
Annals of Pharmacotherapy, 2023Prashant Kaushik +3 more
openaire +2 more sources